MME and Hyperkalemia: Third, the care of HF patients has significantly changed over these past two decades and, likely, the clinical course of patients from the early or mid-2000s differed significantly from what we observe in current clinical practice, not just due to the adoption of angiotensin receptor and neprilysin inhibition, SGLT inhibitors, and to some extent, intravenous iron in HFrEF, but also the emphasis on maximizing all GDMT agents, even with the use of agents to treat GDMT-induced hyperkalemia if needed.